Effect of SGLT2 inhibitors on anemia and their possible clinical implications

被引：0

作者：

Cases, Aleix ^{[1
,2
]}

Cigarran, Secundino ^{[3
]}

Gorriz, Jose Luis ^{[2
,4
]}

Nunez, Julio ^{[5
]}

机构：

[1] Univ Barcelona, Hosp Clin, Serv Nefrol, Barcelona, Spain

[2] Grp Anemia SEN, Madrid, Spain

[3] Hosp Ribera Polusa, Serv Nefrol, Lugo, Spain

[4] Univ Valencia, Hosp Clin Univ, Serv Nefrol, INCLIVA, Valencia, Spain

[5] Univ Valencia, Hosp Clin Univ, Serv Cardiol, INCLIVA,CIBER Cardiovasc, Valencia, Spain

来源：

NEFROLOGIA | 2024年 / 44卷 / 02期

关键词：

SGLT2; inhibitors; Anemia; Diabetes; Heart failure; Chronic kidney disease; HEART-FAILURE; IRON-DEFICIENCY; KIDNEY-DISEASE; EMPAGLIFLOZIN; DAPAGLIFLOZIN; MORTALITY; CANAGLIFLOZIN; HEMATOCRIT; MEDIATORS; INSIGHTS;

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Sodium -glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated cardiovascular and renal benefits in patients with type 2 diabetes mellitus, heart failure, or chronic kidney disease. Since the first studies with these drugs, an initial increase in hemoglobin/hematocrit levels was observed, which was attributed to an increase in hemoconcentration associated with its diuretic effect, although it was soon seen that these drugs increased erythropoietin levels and erythropoiesis, and improved iron metabolism. Mediation studies found that the increase in hemoglobin was strongly associated with the cardiorenal benefits of these drugs. In this review, we discuss the mechanisms for improving erythropoiesis and the implication of the increase in hemoglobin on the cardiorenal prognostic benefit of these drugs. (c) 2023 Sociedad Espa & ntilde;ola de Nefrolog & iacute;a. Published by Elsevier Espa & ntilde;a, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/ by-nc-nd/4.0/).

引用

页码：165 / 172

页数：8

共 80 条

[1] Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes [J].

Aberle, Jens ;

Menzen, Markus ;

Schmid, Sebastian M. ;

Terkamp, Christoph ;

Jaeckel, Elmar ;

Rohwedder, Katja ;

Scheerer, Markus F. ;

Xu, John ;

Tang, Weifeng ;

Birkenfeld, Andreas L. .

SCIENTIFIC REPORTS, 2020, 10 (01)

[2] Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial [J].

Andersen, Camilla Fuchs ;

Omar, Massar ;

Glenthoj, Andreas ;

El Fassi, Daniel ;

Moller, Holger J. ;

Kurtzhals, Jorgen A. Lindholm ;

Styrishave, Bjarne ;

Kistorp, Caroline ;

Tuxen, Christian ;

Poulsen, Mikael K. ;

Faber, Jens ;

Kober, Lars ;

Gustafsson, Finn ;

Moller, Jacob E. ;

Schou, Morten ;

Jensen, Jesper .

EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 (02) :226-234

[3] Empagliflozin in Heart Failure with a Preserved Ejection Fraction [J].

Anker, Stefan D. ;

Butler, Javed ;

Filippatos, Gerasimos ;

Ferreira, Joao P. ;

Bocchi, Edimar ;

Boehm, Michael ;

Brunner-La Rocca, Hans-Peter ;

Choi, Dong-Ju ;

Chopra, Vijay ;

Chuquiure-Valenzuela, Eduardo ;

Giannetti, Nadia ;

Gomez-Mesa, Juan Esteban ;

Janssens, Stefan ;

Januzzi, James L. ;

Gonzalez-Juanatey, Jose R. ;

Merkely, Bela ;

Nicholls, Stephen J. ;

Perrone, Sergio V. ;

Pina, Ileana L. ;

Ponikowski, Piotr ;

Senni, Michele ;

Sim, David ;

Spinar, Jindrich ;

Squire, Iain ;

Taddei, Stefano ;

Tsutsui, Hiroyuki ;

Verma, Subodh ;

Vinereanu, Dragos ;

Zhang, Jian ;

Carson, Peter ;

Lam, Carolyn Su Ping ;

Marx, Nikolaus ;

Zeller, Cordula ;

Sattar, Naveed ;

Jamal, Waheed ;

Schnaidt, Sven ;

Schnee, Janet M. ;

Brueckmann, Martina ;

Pocock, Stuart J. ;

Zannad, Faiez ;

Packer, Milton .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (16) :1451-1461

[4] Hypoxia-inducible factor-1α is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy [J].

Bessho, Ryoichi ;

Takiyama, Yumi ;

Takiyama, Takao ;

Kitsunai, Hiroya ;

Takeda, Yasutaka ;

Sakagami, Hidemitsu ;

Ota, Tsuguhito .

SCIENTIFIC REPORTS, 2019, 9 (1)

[5] Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure [J].

Bhatt, Deepak L. ;

Szarek, Michael ;

Steg, P. Gabriel ;

Cannon, Christopher P. ;

Leiter, Lawrence A. ;

McGuire, Darren K. ;

Lewis, Julia B. ;

Riddle, Matthew C. ;

Voors, Adriaan A. ;

Metra, Marco ;

Lund, Lars H. ;

Komajda, Michel ;

Testani, Jeffrey M. ;

Wilcox, Christopher S. ;

Ponikowski, Piotr ;

Lopes, Renato D. ;

Verma, Subodh ;

Lapuerta, Pablo ;

Pitt, Bertram .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (02) :117-128

[6] Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease [J].

Bhatt, Deepak L. ;

Szarek, Michael ;

Pitt, Bertram ;

Cannon, Christopher P. ;

Leiter, Lawrence A. ;

McGuire, Darren K. ;

Lewis, Julia B. ;

Riddle, Matthew C. ;

Inzucchi, Silvio E. ;

Kosiborod, Mikhail N. ;

Cherney, David Z. I. ;

Dwyer, Jamie P. ;

Scirica, Benjamin M. ;

Bailey, Clifford J. ;

Diaz, Rafael ;

Ray, Kausik K. ;

Udell, Jacob A. ;

Lopes, Renato D. ;

Lapuerta, Pablo ;

Steg, P. Gabriel .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (02) :129-139

[7] Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes [J].

Cannon, Christopher P. ;

Pratley, Richard ;

Dagogo-Jack, Samuel ;

Mancuso, James ;

Huyck, Susan ;

Masiukiewicz, Urszula ;

Charbonnel, Bernard ;

Frederich, Robert ;

Gallo, Silvina ;

Cosentino, Francesco ;

Shih, Weichung J. ;

Gantz, Ira ;

Terra, Steven G. ;

Cherney, David Z. I. ;

McGuire, Darren K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (15) :1425-1435

[8] Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial [J].

Cherney, David Z. I. ;

Charbonnel, Bernard ;

Cosentino, Francesco ;

Dagogo-Jack, Samuel ;

McGuire, Darren K. ;

Pratley, Richard ;

Shih, Weichung J. ;

Frederich, Robert ;

Maldonado, Mario ;

Pong, Annpey ;

Cannon, Christopher P. .

DIABETOLOGIA, 2021, 64 (06) :1256-1267

[9] Anemia and diabetes [J].

Deray, G ;

Heurtier, A ;

Grimaldi, A ;

Vacher, VL ;

Bagnis, CI .

AMERICAN JOURNAL OF NEPHROLOGY, 2004, 24 (05) :522-526

[10] Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF [J].

Docherty, Kieran F. ;

Welsh, Paul ;

Verma, Subodh ;

De Boer, Rudolf A. ;

O'Meara, Eileen ;

Bengtsson, Olof ;

Kober, Lars ;

Kosiborod, Mikhail N. ;

Hammarstedt, Ann ;

Langkilde, Anna Maria ;

Lindholm, Daniel ;

Little, Dustin J. ;

Sjostrand, Mikaela ;

Martinez, Felipe A. ;

Ponikowski, Piotr ;

Sabatine, Marc S. ;

Morrow, David A. ;

Schou, Morten ;

Solomon, Scott D. ;

Sattar, Naveed ;

Jhund, Pardeep S. ;

McMurray, John J., V .

CIRCULATION, 2022, 146 (13) :980-994

← 1 2 3 4 5 6 7 8 →